Skip to main content

Mendus to participate in upcoming conferences in April 2023 and to hold investor call following Annual Report publication on April 17th

Written by Customer Service on . Posted in Public Companies.

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:


Innovation for Health

Rotterdam, The Netherlands, April 6, 2023

Erik Manting, CEO of Mendus, will be part of a panel discussion on partnerships and deal-making.

https://www.hyphenprojects.nl/i4h


AACR Annual Meeting 2023

Orlando, FL, USA, April 14–19, 2023

Mendus to present interim data from the ALISON trial in ovarian cancer.

https://www.aacr.org/meeting/aacr-annual-meeting-2023/


Kempen’s 14th Life Sciences Conference

Amsterdam, The Netherlands, April 25-26, 2023

Mendus’ leadership team will participate and Erik Manting, CEO of Mendus, will give a presentation at the conference.

https://www.vanlanschotkempen.com/en-nl/investment-banking/equities/life-sciences-and-healthcare/life-sciences-conference 

Additionally, Mendus will host an online event for shareholders on April 17, in conjunction with the publication of the company’s Annual Report 2022.


Online event in conjunction with the publication of the Annual Report 2022

Date: 17 April 2023

Time: 10.00 – 10.30 CET

Registration via the registration link: https://edge.media-server.com/mmc/p/upb3kyua

A replay of the webcast will be available via the corporate website following the live event.


FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com


INVESTOR RELATIONS
Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: cdavis@lifesciadvisors.com


MEDIA RELATIONS
Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu


ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.